Kapp, F. G. Et Al. 2023. C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib. CLINICAL IMMUNOLOGY , vol.256 .

Kapp, F. G., Kretschmer, S., Beckmann, C. C., Wäsch, L., Molitor, A., Carapito, R., ... Schubert, M.(2023). C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib. CLINICAL IMMUNOLOGY , vol.256.

Kapp, Friedrich Et Al. "C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib," CLINICAL IMMUNOLOGY , vol.256, 2023

Kapp, Friedrich G. Et Al. "C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib." CLINICAL IMMUNOLOGY , vol.256, 2023

Kapp, F. G. Et Al. (2023) . "C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib." CLINICAL IMMUNOLOGY , vol.256.

@article{article, author={Friedrich G. Kapp Et Al. }, title={C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib}, journal={CLINICAL IMMUNOLOGY}, year=2023}